FDA Inspection
SCA Pharmaceuticals, LLCSCA Pharmaceuticals, LLC – FDA Inspection, Oct 20, 2023
Record Details
This FDA Inspection record concerns SCA Pharmaceuticals, LLC, with an inspection on October 20, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 8ed46b4e-f317-4436-8ba7-6ec1a985a96b
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1221018
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
20- 21 CFR 211.68(b)Computer control of master formula records
- FD&C Act 503B(a)(10)(A)Drug product labels, fails to include
- 21 CFR 211.192Investigations of discrepancies, failures
- 21 CFR 211.103Actual vs. theoretical yields not determined
- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.22(a)Lack of quality control unit
- 21 CFR 211.67(b)Written procedures not established/followed
- 21 CFR 211.63Equipment Design, Size and Location
- 21 CFR 211.42(c)(10)(iv)Environmental Monitoring System
- 21 CFR 211.198(a)Complaint Handling Procedure
Showing 10 of 20 citations.
Full citation text and observation details available on the Dashboard.
Other FDA inspections of SCA Pharmaceuticals, LLC
3| Date | Classification | Office | Project area |
|---|---|---|---|
| March 13, 2026 | Not classified | New England District Office | Drug Quality Assurance |
| December 20, 2024 | VAI | New England District Office | Drug Quality Assurance |
| March 5, 2018 | Not classified | New England District Office | Drug Quality Assurance |
Other documents for SCA Pharmaceuticals, LLC
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.